Schematic computer artwork of the monoclonal antibody Blinatumomab, a bi-specific T-cell engager (BiTE). Blinatumomab (trade name) specifically target

---

Schematic computer artwork of the monoclonal antibody Blinatumomab, a bi-specific T-cell engager (BiTE). Blinatumomab (trade name) specifically targets the CD19 antigen present on B cells. Blinatumomab enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor. The drug works by linking these two cell types and activating the T cell to exert cytotoxic activity on the target is used as a second-line treatment against acute lymphoblastic leukemia. The background is depicting a cancer cell.

---

Size: 5000px × 5000px
Photo credit: © ALFRED PASIEKA/SCIENCE PHOTO LIBRARY / Alamy / Afripics
License: Licensed
Model Released: No

Keywords: -, -cell, -line, activating, activity, acute, adult, antibodies, antibody, antigen, artwork, bi-specific, binding, bites, blinatumomab, cancer, cd19, cd3, cell, cells, cgi, combines, cytotoxic, digitally-generated, drug, engagers, illustration, image, leukaemia, leukemia, linking, lymphoblastic, malignant, molecule, monoclonal, patients, potential, receptor, sites, target, therapeutic, treatment, tumor, tumour